HPP971

HPP971 is a synthetic, orally bioavailable small molecule that acts as a dual modulator by **inhibiting BACH1** (BTB domain and CNC homolog 1) and **activating Nrf2** (nuclear factor erythroid 2-related factor 2), leading to activation of the antioxidant response element (ARE) pathway. This mechanism results in increased expression of antioxidant and cytoprotective genes (e.g., HMOX1), elevation of intracellular glutathione, suppression of pro-inflammatory cytokine production, and inhibition of immune cell activation. HPP971 exhibits anti-inflammatory, cytoprotective, and hepatoprotective properties. Its lead development indications are for kidney diseases and renal disorders, with therapeutic interest also noted in neurodegenerative disorders and inflammation. Developed originally by vTv Therapeutics and later licensed to Anteris Bio, HPP971 has completed two phase 1 clinical studies and reached phase 2 development for kidney disorders. In animal models, it has shown efficacy comparable to existing Nrf2 activators such as dimethyl fumarate, but via a non-electrophilic and potentially safer mechanism[1][2][3][5][7].

Brand names

ANT-401ANT401ANT 401

Other names

ANT-401ANT401ANT 401HPP 971HPP971HPP-971